International consensus on quality standards for multiple sclerosis care: results from a modified Delphi process

Jeremy Hobart, Amy Bowen, Lucy Eberhard, George Pepper and Gavin Giovannoni

Professor Jeremy Hobart, Plymouth University Peninsula Schools of Medicine and Dentistry

Sunday 17 June 2018, Lisbon, Portugal
This research was carried out as part of the MS Brain Health initiative. MS Brain Health activities and supporting materials have been funded by grants from Actelion, Celgene and Sanofi Genzyme and by educational grants from Biogen, F. Hoffmann-La Roche and Merck KGaA, all of whom had no influence on the content.

J Hobart has received consulting fees, honoraria, support to attend meetings or research support from Acorda, Asubio Pharma, Bayer Schering Pharma, Biogen Idec, F. Hoffmann-La Roche, Sanofi Genzyme, Merck Serono, Novartis, Oxford Health Policy Forum and Teva.

A Bowen has nothing to disclose.

L Eberhard is an employee of Oxford PharmaGenesis.

G Pepper has received consulting fees from Biogen, Novartis, Oxford Health Policy Forum and Teva.

G Giovannoni has received consulting fees from AbbVie, Almirall, Atara Biotherapeutics, Biogen, Celgene, GlaxoSmithKline, MedDay Pharmaceuticals, Merck and Company (US), Merck Group (Europe), Novartis, Oxford Health Policy Forum, Roche, Sanofi Genzyme, Synthon, Takeda, Teva Pharmaceutical Industries Ltd., UCB; and grant/research support from Biogen, Sanofi Genzyme and Takeda.
Background and aims

Background:
- **Brain health: time matters in multiple sclerosis** highlights the need for timely diagnosis and management
  - Variability in practice and care quality
  - Absence of globally accepted standards
- Quality standards would provide a benchmark for timely care globally

Aim:
Define ‘core’, ‘achievable’ and ‘aspirational’ standards for the timing of **key steps in the MS care pathway** (to reflect minimum, good and high standards, respectively)

---

The Delphi process – modified

- A structured way to reach consensus among experts, using surveys
- Opinions remain anonymous

<table>
<thead>
<tr>
<th>Delphi Panel (N = 29)</th>
<th>Reviewing Group (N = 31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Round 1 – comment on principles (n = 27)</td>
<td>Comment on results</td>
</tr>
<tr>
<td>Round 2 – suggest time frames (n = 24)</td>
<td>Comment on statements</td>
</tr>
<tr>
<td>Round 3 – choose time frames (n = 24)</td>
<td>Comment on statements</td>
</tr>
<tr>
<td>Round 4 – vote on statements (n = 21)</td>
<td></td>
</tr>
<tr>
<td>Round 5 – vote on statements (n = 21)</td>
<td></td>
</tr>
</tbody>
</table>

- **Four Chairs** led the process
- **Delphi Panel** of MS neurologists voted
- **Reviewing Group** commented (comprised MS nurses, people with MS and allied health professionals)
Key stages in the MS care pathway assessed

- **6 domains** of care reviewed

- **27 statements** considered, at three levels

- **21 steps** in the pathway achieved consensus* for core, achievable and aspirational standards of MS care
  - Thresholds for consensus were at least 75% agreement and at least 66% participation compared with round 1

*Consensus was reached on the majority of core (25/27), achievable (25/27) and aspirational (22/27) time frames for events spanning the MS care pathway. The Panel also reached agreement on four statements that were not time-limited.
Example timings agreed from two domains

**Example 1:** time from referral to completion of diagnostic workup

- **Referral & diagnosis**
  - Core: 2 months
  - Achievable: 4 weeks
  - Aspirational: 7 days

**Example 2:** time from diagnosis to a discussion on the aims of treatment with patient

- **Treatment decisions**
  - Core: 4 weeks
  - Achievable: 2 weeks
  - Aspirational: 7 days

*Consensus was reached on the majority of core (25/27), achievable (25/27) and aspirational (22/27) time frames for events spanning the MS care pathway. The Panel also reached agreement on four statements that were not time-limited.*
Implications and next steps

- First study to establish **consensus on timing** of key steps in the MS care pathway, agreed internationally by MS experts
- A benchmark that will help individual MS services globally strive for the **highest level of care**
  - Not a means to criticize MS teams
- **Tools are being developed** for clinics and people with MS, based on these standards
- Clinics will **gather data** that will help with:
  - local problem-solving
  - national policymaking
  - international alignment on MS care